Treatment of anaplastic glioma

Cancer Treatment and Research

Volumn 163, Issue , 2015, Pages 89-101

  Wick, Wolfgang ^a   Wiestler, Benedikt ^a   Platten, Michael ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

1p 19q codeletion; 450k methylation arrays; ATRX; Brain tumor; CATNON; CCNU; CODEL; EORTC; Glioma; IDH; MGMT; NDRG1; NOA; Oligodendroglial tumor; PCV; Radiotherapy; RTOG; Steroid; Temozolomide

Indexed keywords

ALPHA THALASSEMIA MENTAL RETARDATION SYNDROME X LINKED PROTEIN; CARMUSTINE; ISOCITRATE DEHYDROGENASE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; PROTEIN P53; PROTEIN TYROSINE KINASE; TELOMERASE REVERSE TRANSCRIPTASE; TEMOZOLOMIDE; TUMOR MARKER; UNCLASSIFIED DRUG; VINCRISTINE;

ADJUVANT THERAPY; ALLERGIC REACTION; ARTICLE; BONE MARROW SUPPRESSION; BRAIN SURGERY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL TRIAL (TOPIC); COGNITION; CPG ISLAND; GENE MUTATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MEDICAL DECISION MAKING; MICROSCOPY; MULTIPLE CYCLE TREATMENT; NERVOUS SYSTEM FUNCTION; NEUROPATHY; OVERALL SURVIVAL; PHENOTYPE; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN METHYLATION; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; TREATMENT DURATION; WILD TYPE; ALGORITHM; BRAIN NEOPLASMS; GENETICS; GLIOMA; MUTATION;

ALGORITHMS; BRAIN NEOPLASMS; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION;

EID: 84916623122     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-319-12048-5_6     Document Type: Article

References (39)

1. Gorlia T, Delattre JY, Brandes AA et al (2013) New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. Eur J Cancer 49:3477–3485
2. Olson JD, Riedel E, DeAngelis LM (2000) Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54:1442–1448
3. Chang EF, Potts MB, Keles GE et al (2008) Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 108:227–235
4. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W (2014) European association for neuro-oncology (EANO) task force on malignant gliomaEANO guideline on the diagnosis and treatment of malignant glioma. Lancet Oncol 15(9):e395–403
5. Surma-aho O, Niemelä M, Vilkki J et al (2001) Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 56:1285–1290
6. Taphoorn MJ, Schiphorst AK, Snoek FJ et al (1994) Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol 36:48–54
7. Klein M, Heimans JJ, Aaronson NK et al (2002) Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360:1361–1368
8. Laack NN, Brown PD, Ivnik RJ et al (2005) North Central Cancer Treatment Group. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys 63:1175–1183
9. Douw L, Klein M, Fagel SS et al (2009) Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8:810–818
10. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N Engl J Med 352:987–996
11. Baumert B, Mason WP, Ryan G et al (2013) Temozolomide chemotherapy vs. radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC study #22033-26033). J Clin Oncol 31, suppl; abstr 2007
12. Wick W, Hartmann C, Engel C et al (2009) NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide. J Clin Oncol 27:5874–5880
13. Yung WKA, Prados MD, Yaga-Tur R et al (1999) for the Temodal Brain Tumor Group. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17, 2762–2771
14. Yung WKA, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593
15. Cairncross JG, Macdonald DR (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23(4):360–364
16. Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, Wilson CB (1980) Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64(2–3):237–244
17. Van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer. J Clin Oncol 24:2715–2722
18. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714
19. Wick W, Platten M, Meisner C et al (2012) Chemotherapy versus radiotherapy for malignant astrocytoma in the elderly. Lancet Oncol. 13(7):707–715
20. Wick A et al (2007) Efficacy and tolerability of temozolomide in an one week on/one week off regimen in patients with recurrent glioma. J Clin Oncol 25:3357–3361
21. Perry JR et al (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051–2057
22. Gilbert M, Mehta M, Aldape K et al (2011) RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide with a dose-dense schedule in newly diagnosed glioblastoma. J Clin Oncol 29:2006
23. Tabatabai G, Wick W, Steinbach JP, Wick A, Schnell O, et al. MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial. J Clin Oncol Suppl Abstract 2015 (2014)
24. Wiestler B, Capper D, Sill M, et al. Integrated epigenetic and copy-number profiling identifies three clinically and biologically relevant groups of anaplastic gliomas
25. Wick W, Meisner C, Hentschel B et al (2013) IDH1 mutations determine the prognostic versus predictive value of MGMT promoter methylation in malignant gliomas. Neurology 81:1515–1522
26. van den Bent MJ, Brandes AA, Taphoorn MJB et al (2013) Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951. J Clin Oncol 31:344–350
27. Cairncross G, Wang M, Shaw E et al (2013) Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402. J Clin Oncol 31:337–343
28. Gállego Pérez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011 Aug 1;29(22):3050-5
29. Reifenberger G, Hentschel B, Felsberg J et al (2012) Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 131(6):1342–1350
30. Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926
31. Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Müller W, Plass C, Weller M, Wick W for the Neurooncology Working Group (NOA) of the German Cancer Society (2013) Malignant gliomas of elderly patients have a distinct molecular profile: an analysis of the NOA-08 study collective. Neurooncol 15(8):1017–1026
32. Johnson DR et al (2012) Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro Oncol 14:808–816
33. Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, Huse JT, Mehta MP, Curran WJ Jr (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32(8):783–790
34. Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718
35. Weiler M, Blaes J, Pusch S et al (2014) The mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci USA 111:409–414
36. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C et al (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340 (6132):626–630
37. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balss J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller S, Okun J, Stefanovic S, Riemer AB, Sahin U, Friese M, Beckhove P, von Deimling A, Wick W, Platten M (2014). A vaccine targeting mutant IDH1 induces antitumor immunity. Nature accepted
38. Erdem-Eraslan L, Gravendeel LA, de Rooi J et al (2013) Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. J Clin Oncol 31 (3):328–336
39. Wiestler B, Capper D, Holland-Letz T et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451